Canterbury DHB
Patients who are not entered into the AML19 trial will be treated with 4 cycles of chemotherapy DA X 2 and HDAC X 2.
Cycle 1 |
DA 3 + 10 |
Daunorubicin 60 mg/m2 days 1, 3, and 5 (3 doses). Cytarabine 100 mg/m2 Q12H days 1–10 (20 doses). |
Cycle 2 |
DA 3 + 8 |
Daunorubicin 50 mg/m2 days 1, 3, and 5 (3 doses). Cytarabine 100 mg/m2 Q12H days 1–8 (16 doses). |
Cycle 3 and 4 |
|
Cytarabine 1500 mg/m2 Q12H on days 1, 3, and 5 (6 doses). |
References:
Topic Code: 32084